Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to further advance its biomarker discovery platform.
Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 3.1 million in a pre-Series A round led by Swisscom Ventures.
4FO Ventures, HEMEX and a private investor joined the financing round, alongside the
existing shareholders who increased their investments. Dr. Jean-Pierre Rosat, CEO of 4FO
Ventures, will join the Board of Directors of Scailyte.
Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell
technologies and their proprietary single-cell data analysis platform ScaiVision™
ScaiVision™ offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
“We are continuously developing and utilizing our data analytics platform ScaiVision™ for biomarker discovery from single-cell data” says Peter Nestorov, CEO of Scailyte AG. “The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analyzing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast emerging Single-Cell Analysis field, enabling various clinical applications of single-cell data“.
The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline, and drive the development of the first clinical applications using single-cell biomarkers.
Dominique Mégret, Head of Swisscom Ventures, commented “Since we began supporting Scailyte in 2018 we have been impressed by the team and the positive results. We see an opportunity to leverage their AI technology to build a portfolio of biomarkers which will have a positive effect on the speed of patient diagnosis.”
Matthieu Berger, CFA, the General Partner who led 4FO’s due diligence added: “We are very happy to
support Scailyte and join a high quality group of investors in this endeavor. Scailyte is at the forefront
of single-cell analysis system development and holds the potential to be one of the future leaders in
the field. Mixing AI with the most advanced biological analytic tools, makes it for a very interesting
and intriguing company.”
Also contributing to this financing round is HEMEX, the start-up incubator whose CEO Pascal Winnen
is Scailyte’s Chairman: ”It is a pleasure to work with the dynamic and ambitious group of scientists
that drives Scailyte’s rapid progress. The first results of the powerful biomarker discovery platform
have exceeded all expectations. We are proud to continue to support Scailyte to turn this knowledge
into products that will have a lasting impact on patients’ lives.”
Swisscom Ventures is the venture capital arm of the Swisscom Group, the leading
telecommunications and one of the leading IT companies in Switzerland. Since its inception in 2007,
Swisscom has acquired minority stakes in over 60 companies with a strong focus on digital media, IT
and telecommunications. Swisscom Ventures offices are located in the innovation hubs of Switzerland
(Zurich and Lausanne) and the USA (Silicon Valley). As a strategic investor, they invest in companies
that are strategically relevant to the Swisscom business. In return, they offer entrepreneurs access to
telecommunications expertise, technical infrastructure and marketing channels – in addition to
financial support. For more information: www.swisscom.ch/ventures
4FO Ventures is a Luxembourg domiciled fund, focused on early-stage companies in Switzerland. The
fund invests in artificial intelligence related projects and medtech companies, with a special
emphasis on ethical and highly innovative projects. The 4FO team is composed of successful and
seasoned entrepreneurs, who makes substantial efforts to support the portfolio companies in
installing Good Management Practices very early on and provide networking. The fund is also
engaged in the search for co-investors specialized in the industries of the portfolio companies on
subsequent financing rounds. Luxrise 4FO Ventures is managed by Berger, van Berchem & Cie SA
based in Geneva and Lausanne.
HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the
Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in
vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored
solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX
helps start-ups in their efforts to find non-dilutive and dilutive funding. More at www.hemex.eu
Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is
supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning
several national and international start-up competitions, and is the beneficiary of significant research
grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial
Intelligence, Software development, Finance, Marketing and Sales.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised
pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and
have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.
Recent News
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...
Recent News
Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)
Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Scailyte Strengthens Its Leadership
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...
Recent News
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Recent News
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...
Recent News
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...
Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)
Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Scailyte Strengthens Its Leadership
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...
Recent News
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...